|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sinn M, Bahra M, Denecke T, Travis S,
Pelzer U and Riess H: Perioperative treatment options in resectable
pancreatic cancer-how to improve long-term survival. World J
Gastrointest Oncol. 8:248–257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Delpu Y, Hanoun N, Lulka H, Sicard F,
Selves J, Buscail L, Torrisani J and Cordelier P: Genetic and
epigenetic alterations in pancreatic carcinogenesis. Current
Genomics. 12:15–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Biankin AV, Waddell N, Kassahn KS, Gingras
MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J,
et al: Pancreatic cancer genomes reveal aberrations in axon
guidance pathway genes. Nature. 491:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peng DF, Kanai Y, Sawada M, Ushijima S,
Hiraoka N, Kosuge T and Hirohashi S: Increased DNA
methyltransferase 1 (DNMT1) protein expression in precancerous
conditions and ductal carcinomas of the pancreas. Cancer Sci.
96:403–408. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang J, Wei X, Wu Q, Xu Z, Gu D, Jin Y,
Shen Y, Huang H, Fan H and Chen J: Clinical significance of the
expression of DNA methyltransferase proteins in gastric cancer. Mol
Med Rep. 4:1139–1143. 2011.PubMed/NCBI
|
|
7
|
He S, Wang F, Yang L, Guo C, Wan R, Ke A,
Xu L, Hu G, Xu X, Shen J and Wang X: Expression of DNMT1 and DNMT3a
are regulated by GLI1 in human pancreatic cancer. PLoS One.
6:e276842011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang JJ, Zhu Y, Zhu Y, Wu JL, Liang WB,
Zhu R, Xu ZK, Du Q and Miao Y: Association of increased DNA
methyltransferase expression with carcinogenesis and poor prognosis
in pancreatic ductal adenocarcinoma. Clin Transl Oncol. 14:116–124.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao J, Wang L, Xu J, Zheng J, Man X, Wu H,
Jin J, Wang K, Xiao H, Li S and Li Z: Aberrant DNA
methyltransferase expression in pancreatic ductal adenocarcinoma
development and progression. J Exp Clin Cancer Res. 32:862013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghoshal K and Bai S: DNA
methyltransferases as targets for cancer therapy. Drugs Today
(Barc). 43:395–422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mutze K, Langer R, Schumacher F, Becker K,
Ott K, Novotny A, Hapfelmeier A, Höfler H and Keller G: DNA
methyltransferase 1 as a predictive biomarker and potential
therapeutic target for chemotherapy in gastric cancer. Eur J
Cancer. 47:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagaraju GP, Zhu S, Wen J, Farris AB,
Adsay VN, Diaz R, Snyder JP, Mamoru S and El-Rayes BF: Novel
synthetic curcumin analogues EF31 and UBS109 are potent DNA
hypomethylating agents in pancreatic cancer. Cancer Lett.
341:195–203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vaccaro V, Sperduti I and Milella M:
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N
Engl J Med. 365:768–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Poplin E, Feng Y, Berlin J, Rothenberg ML,
Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P,
et al: Phase III, randomized study of gemcitabine and oxaliplatin
versus gemcitabine (fixed-dose rate infusion) compared with
gemcitabine (30-min infusion) in patients with pancreatic carcinoma
E6201: A trial of the eastern cooperative oncology group. J Clin
Oncol. 27:3778–3785. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH,
Kovar P, Li G, Wang G, Tao ZF, Tong Y, et al: Selective Chk1
inhibitors differentially sensitize p53-deficient cancer cells to
cancer therapeutics. Int J Cancer. 119:2784–2794. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morgan MA, Parsels LA, Parsels JD,
Mesiwala AK, Maybaum J and Lawrence TS: Role of checkpoint kinase 1
in preventing premature mitosis in response to gemcitabine. Cancer
Res. 65:6835–6842. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma CX, Cai S, Li S, Ryan CE, Guo Z,
Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, et al: Targeting
Chk1 in p53-deficient triple-negative breast cancer is
therapeutically beneficial in human-in-mouse tumor models. J Clin
Invest. 122:1541–1552. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gadhikar MA, Sciuto MR, Alves MV,
Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN
and Frederick MJ: Chk1/2 inhibition overcomes the cisplatin
resistance of head and neck cancer cells secondary to the loss of
functional p53. Mol Cancer Ther. 12:1860–1873. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Albiges L, Goubar A, Scott V, Vicier C,
Lefèbvre C, Alsafadi S, Commo F, Saghatchian M, Lazar V, Dessen P,
et al: Chk1 as a new therapeutic target in triple-negative breast
cancer. Breast. 23:250–258. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bargiela-Iparraguirre J, Prado-Marchal L,
Fernandez-Fuente M, Gutierrez-González A, Moreno-Rubio J,
Muñoz-Fernandez M, Sereno M, Sanchez-Prieto R, Perona R and
Sanchez-Perez I: CHK1 expression in gastric cancer is modulated by
p53 and RB1/E2F1: Implications in chemo/radiotherapy response. Sci
Rep. 6:215192016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F,
Xie X, Zhou C and Lu W: Suppressed miR-424 expression via
upregulation of target gene Chk1 contributes to the progression of
cervical cancer. Oncogene. 32:976–987. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ben-Yehoyada M, Wang LC, Kozekov ID, Rizzo
CJ, Gottesman ME and Gautier J: Checkpoint signaling from a single
DNA interstrand crosslink. Mol Cell. 35:704–715. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiao Y, Ramiscal J, Kowanetz K, Del Nagro
C, Malek S, Evangelista M, Blackwood E, Jackson PK and O'Brien T:
Identification of preferred chemotherapeutics for combining with a
CHK1 inhibitor. Mol Cancer Ther. 12:2285–2295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barnard D, Diaz HB, Burke T, Donoho G,
Beckmann R, Jones B, Barda D, King C and Marshall M: LY2603618, a
selective CHK1 inhibitor, enhances the anti-tumor effect of
gemcitabine in xenograft tumor models. Invest New Drugs. 34:49–60.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Røe OD, Szulkin A, Anderssen E, Flatberg
A, Sandeck H, Amundsen T, Erlandsen SE, Dobra K and Sundstrøm SH:
Molecular resistance fingerprint of pemetrexed and platinum in a
long-term survivor of mesothelioma. PLoS One. 7:e405212012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen
G, Yang L, Li B, Huang P, Chen D, et al: CHK1 targets spleen
tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J
Clin Invest. 122:2165–2175. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koniaras K, Cuddihy AR, Christopoulos H,
Hogg A and O'Connell MJ: Inhibition of Chk1-dependent G2 DNA damage
checkpoint radiosensitizes p53 mutant human cells. Oncogene.
20:7453–7463. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Flis S, Gnyszka A and Flis K: DNA
methyltransferase inhibitors improve the effect of chemotherapeutic
agents in SW48 and HT-29 colorectal cancer cells. PLoS One.
9:e923052014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Radisavljevic Z: AKT as locus of cancer
multidrug resistance and fragility. J Cell Physiol. 228:671–674.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim R, Yamauchi T, Husain K, Sebti S and
Malafa M: Triciribine phosphate monohydrate, an AKT inhibitor,
enhances gemcitabine activity in pancreatic cancer cells.
Anticancer Res. 35:4599–4604. 2015.PubMed/NCBI
|
|
33
|
Xiu P, Dong X, Dong X, Xu Z, Zhu H, Liu F,
Wei Z, Zhai B, Kanwar JR, Jiang H, et al: Secretory clusterin
contributes to oxaliplatin resistance by activating Akt pathway in
hepatocellular carcinoma. Cancer Sci. 104:375–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stronach EA, Chen M, Maginn EN, Agarwal R,
Mills GB, Wasan H and Gabra H: DNA-PK mediates AKT activation and
apoptosis inhibition in clinically acquired platinum resistance.
Neoplasia. 13:1069–1080. 2011. View Article : Google Scholar : PubMed/NCBI
|
